Showing 1 - 10 of 67
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...
Persistent link: https://www.econbiz.de/10003900791
; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration …
Persistent link: https://www.econbiz.de/10003900852
Persistent link: https://www.econbiz.de/10009753975
; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration …
Persistent link: https://www.econbiz.de/10003909500
Persistent link: https://www.econbiz.de/10011483039
Best-worst scaling (BWS), also known as maximum-difference scaling, is a multiattribute approach to measuring preferences. BWS aims at the analysis of preferences regarding a set of attributes, their levels or alternatives. It is a stated-preference method based on the assumption that...
Persistent link: https://www.econbiz.de/10011459112
Persistent link: https://www.econbiz.de/10009755744
Persistent link: https://www.econbiz.de/10013378216
Persistent link: https://www.econbiz.de/10001796637
Persistent link: https://www.econbiz.de/10013378218